CINECA IRIS Institutional Research Information System

PILERI, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.690
NA - Nord America 2.486
AS - Asia 1.016
AF - Africa 18
SA - Sud America 3
OC - Oceania 1
Totale 6.214
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.433
CN - Cina 607
RU - Federazione Russa 541
UA - Ucraina 374
IE - Irlanda 309
DE - Germania 269
FR - Francia 268
SE - Svezia 245
FI - Finlandia 190
IT - Italia 186
KR - Corea 184
SG - Singapore 111
AT - Austria 104
GB - Regno Unito 101
JP - Giappone 61
PL - Polonia 60
CA - Canada 49
VN - Vietnam 25
BE - Belgio 14
SN - Senegal 14
GR - Grecia 12
SA - Arabia Saudita 11
IN - India 7
HK - Hong Kong 6
NL - Olanda 5
BR - Brasile 3
MU - Mauritius 3
MX - Messico 3
AL - Albania 2
ES - Italia 2
NO - Norvegia 2
PT - Portogallo 2
RO - Romania 2
AS - Samoa Americane 1
BY - Bielorussia 1
CH - Svizzera 1
CR - Costa Rica 1
ID - Indonesia 1
TR - Turchia 1
TW - Taiwan 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 6.214
Salva come PNG Salva come JPEG
Città #
Beijing 526
Chandler 441
Dublin 309
Jacksonville 199
Villeurbanne 186
Medford 145
Princeton 109
Vienna 104
Ann Arbor 97
Dearborn 90
Nyköping 90
Houston 89
Ashburn 83
Milan 64
Wilmington 61
Saint Petersburg 59
Warsaw 59
Fairfield 54
Fremont 54
Singapore 50
San Mateo 40
Toronto 32
Boardman 28
Verona 28
Boston 23
Torino 22
Woodbridge 21
Norwalk 20
Dong Ket 15
Brussels 14
Düsseldorf 13
Hefei 13
Seattle 13
Valdagno 13
Mountain View 12
Falls Church 11
Nanjing 11
New York 11
Lachine 9
Kunming 7
Ottawa 7
Redwood City 7
Kharkiv 6
Mcallen 6
Nanchang 6
Tappahannock 6
Washington 6
Baotou 5
Guangzhou 5
Los Angeles 5
Munich 5
Pune 5
Zhengzhou 5
Auburn Hills 4
Cambridge 4
Chicago 4
Hebei 4
Hong Kong 4
Jinan 4
Orio Canavese 4
Pisa 4
Detroit 3
Florence 3
Nürnberg 3
Redmond 3
Rome 3
San Diego 3
Venice 3
Grafing 2
Hangzhou 2
Margherita Di Savoia 2
Mesa 2
Monmouth Junction 2
Monoxilitai 2
Monterrey 2
Naples 2
Paris 2
Phoenixville 2
Porto 2
Seoul 2
Shanghai 2
Taizhou 2
Tiranë 2
Trofarello 2
Venaria 2
Vigevano 2
A Coruña 1
Aachen 1
Bordeaux 1
Brownsville 1
Buscate 1
Cartago 1
Casoria 1
Central District 1
Centurion 1
Changsha 1
Chengdu 1
Edgewater 1
Edinburgh 1
Forcoli 1
Totale 3.402
Salva come PNG Salva come JPEG
Nome #
Monoclonal antibody purging and autologous bone marrow transplantation in acute myelogenous leukemia in complete remission. 564
Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo) 143
Biology of the human myeloma cell population. I.Macromolecular characteristics. 114
Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. 104
Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin IgG and IgA secreting multiple myelomas 102
Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation. 101
Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy 98
Idiotypic lymphocytes in human monoclonal gammopathies. 95
Antigenic phenotype of myelomonocytic progenitors (CFU-GM) in chronic myeloproliferative disorders. 90
Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (Fl): Updated Results Suggest the Use of R-HDS as Salvage Treatment 86
GM-CSF-exposed peripheral blood progenitors as sole source of stem cells for autologous transplantation in two patients with multiple myeloma 84
An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy. 84
Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. 83
INTERMEDIATE-DOSE CYCLOPHOSPHAMIDE FOLLOWED BY INTERFERON-ALPHA-2B AND PREDNISONE MAINTENANCE THERAPY FOR REFRACTORY MYELOMA 83
Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies:correlation with diagnosis and disease status. 81
MOLECULAR REMISSION IN A MULTIPLE MYELOMA PATIENT AFTER A NON MYELOABLATIVE ALLOGENEIC TRANSPLANT: PROOF OF PRINCIPLE 81
High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients 79
Human homologue of the Moloney Leukemia Virus Integration-4 Locus (MLVI-4), located 20 kb 3' of the myc gene, is rearranged in multiple myelomas. 79
Sequential cyclophosphamide-melphalan (CM) with circulating progenitor cell (CPC) support in multiple myeloma 78
Trophoblast cell line conditioned medium for in vitro culture and antigenic characterization of acute myeloid leukemia clonogenic cells. 78
REAL TIME PCR IN MULTIPLE MYELOMA: QUANTITATIVE ANALYSIS OF TUMOR CONTAMINATION OF STEM CELL HARVESTS 78
Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma. 77
Dual rearrangement of immunoglobulin and T-cell receptor gene in a case of T-cell hairy-cell leukemia. 77
Human myeloma: several subsets of circulating lymphocytes express plasma cell-associated antigens. 76
Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. 76
MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study. 75
Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients. 71
Autologous bone marrow transplantation in acute myeloid leukemia after in-vitro purging with an anti-lacto-N-fucopentaose III antibody and rabbit complement. 71
Current therapeutic options for multiple myeloma. 69
Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue 69
Both early and committed progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF. 68
Cytofluorimetric evaluation of plasma cell proliferative activity in monoclonal gammopathies. 67
High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. 67
Analysis of the breakpoint cluster region in essential thrombocythemia. 66
G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. 65
Clinical and trichoscopic features in 18 cases of Folliculotropic Mycosis Fungoides with scalp involvement 65
Recombinant interferon-gamma in a patient with multiple myeloma. 64
Long-term molecular remission after conventional chemotherapy in a patient with Philadelphia-negative acute lymphoblastic leukemia. 64
Generation of anti-tumour activity by OKT3-stimulation in multiple myeloma: in vitro inhibition of autologous haemopoiesis. 63
Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support. 63
Retinoic acid inhibits the growth of human myeloma cells in vitro. 62
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage 62
PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy. 61
Cyclophosphamide (3.6 g/m2) therapy with G-CSF support for resistant myeloma. 60
Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short interval between drug courses severely impair progenitor mobilization. 60
Conventional induction treatments do not influence overall survival in multiple myeloma. 60
Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas 59
Altered expression of growth-regulated protoncogenes in human malignant plasma cells. 58
High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. 58
Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. 56
Dose-intensive melphalan with stem cell support /CM regimen is effective and well tolerated in elderly myeloma patients. 56
REAL TIME QUANTITATIVE PCR SHOWS THAT PERIPHERAK BLOOD STEM CELL (PBPC) HARVESTS ARE SIGNIFICANTILY LESS CONTAMINATED THAN BONE MARROW (BM) IN MULTIPLE MYELOMA PATIENTS (MM). 55
Mutational activation of N-and K-RAS oncogenes in plasma cell dyscrasia. 54
Conditions influencing the expansion of the circulating hemopoietic progenitor cell compartment. 54
Peripheral blood progenitor cell mobilization in patients with primary refractory lympoma or at first relapse: comparison with patients at diagnosis and impact on clinical outcome. 53
Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma. 53
The generation of alloreactive cytotoxic T lymphocytes (CTL) require the expression of ecto-5' nucleotidase activity. 53
Monoclonal immunoglobulin rearrangement in peripheral lymphocytes of a patient with multiple myeloma. 53
Oral melphalan at diagnosis hampers adeguate collection of peripheral blood progenitor cells in multiple myeloma. 53
Dose- intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. 51
Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer 51
Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. 51
GIMEMA ALL 0183: a multicentric study on adult acute lymphoblastic leukaemia in Italy. 50
Early disappearance of murine plasmocytoma stem cells in long-term bone marrow culture. 50
Selection and characterization of early hematopoietic progenitors using an anti-CD71/SO6 immunotoxin. 49
Multiple myeloma: intensified maintenance therapy with recombinant interferon-alfa-2b plus glucocorticoids. 49
MACOP-B treatment for advanced stage diffuse large cell lymphoma: a multicenter Italian Study. 48
Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. 47
Granulocyte-macrophage colony-stimulating factor to harvest circulating hemopoietic stem cells for autransplantation. 45
Fattori prognostici nel mieloma multiplo. 45
Multiple Myeloma: a tailored therapy for elderly patients. 45
MACOP-B treatment for intermediate and high-grade non-Hodgkin's lymphomas at diagnosis and in relapse. 44
IN MYELOMA PATIENTS TREATED WITH MELPHALAN 100mg/m2 OR MELPHALAN 200mg/m2 OUTCOME IS NOT SIGNIFICANTLY DIFFERENT 43
Recombinant interferon-gamma inhibits the growth of human myeloma cells in vitro. 42
Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. 42
High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. 41
Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. 41
The idiotypic specificities of lymphocytes in human monoclonal gammopathies: analysis with the fluorescence activated cell sorter. 40
Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients. 40
Reduction of plasma fibrinolytic activity following high-dose cyclophosphamide is neutralized in vivo by GM-CSF administration. 40
Haematological support of high-dose sequential chemotherapy: clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas. 40
Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. 40
Durable and complete hematopoietic reconstitution after autografting of rhGM-CSF exposed peripheral blood progenitor cells. 39
Il Mieloma multiplo. 39
Interferon plus glucocorticoids as intensified maintenance therapy prolongs tumor control in refractory myeloma. 39
Feasibility of peripheral blood progenitor cell mobilization and harvest to support chemotherapy intensification in elderly patients with poor prognosis: non-Hodgkin's lymphoma. 38
Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. 38
Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell (PBPC) collections performed after repeated high-dose chemotherapy courses. 36
Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests. 36
Interferon-gamma in multiple myeloma. 36
High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. 36
High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. 34
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey 32
High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: long-term analysis and future developments. 32
Hemopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulkying in indolent lymphoma patients 31
Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. 30
Multiple independent class-switch recombinations occurring within the same clone in myeloma. 30
Idiotypic reactive T cells 30
Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft. 29
Italian expert-based recommendations on the use of photo(chemo)therapy in the management of mycosis fungoides: Results of an e-Delphi consensus 27
Totale 6.424
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.872
article - articoli 0
book - libri 0
conference - conferenze 1.666
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.538
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201926 0 0 0 0 0 0 0 0 0 0 0 26
2019/2020735 9 2 122 28 51 132 109 17 100 69 68 28
2020/2021560 61 12 73 20 50 20 61 8 117 71 26 41
2021/2022789 18 18 18 33 19 14 112 27 20 93 168 249
2022/20231.707 140 99 28 110 126 348 97 74 127 487 51 20
2023/2024481 77 113 30 37 26 62 3 8 2 13 24 86
Totale 6.479